IDEAYA Biosciences Darovasertib Combo Advances Uveal Melanoma Care
South San Francisco, California, USA, April 21, 2026 In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
South San Francisco, California, USA, April 21, 2026 In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has...
Queensbury, New York, USA, April 6, 2026 ESMO Guideline Inclusion Validates CHEMOSAT Therapy In a major milestone for interventional...
South San Francisco, California, USA | March 22, 2026 IDEAYA Biosciences has announced updated guidance on the anticipated topline...
